Company intelligence / Profile preview

Cranbury Pharmaceuticals

Monmouth Junction, New Jersey, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Cranbury Pharmaceuticals, a subsidiary of Tris Pharma, focuses on commercializing and developing high-quality, patient-friendly generic medicines. Its first major product, generic deflazacort oral suspension, received FDA approval for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older. The company markets over 20 generic medicines, many already approved and commercially available, across CNS-related and other therapeutic areas[2][3][4][5][12][14].

Therapeutic areas: Rare DiseasesNeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cranbury Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cranbury Pharmaceuticals.

Explore the full profile